Adenomyosis and Fertility: A Complete Guide

Adenomyosis is a condition in which the endometrial glands and stroma (the tissue that normally lines the inside of the uterus) grow into the myometrium -- the muscular wall of the uterus. Unlike endometriosis, where similar tissue grows outside the uterus, in adenomyosis the tissue burrows inward into the uterine muscle itself.

This misplaced endometrial tissue continues to respond to hormonal signals during the menstrual cycle. It thickens, breaks down, and bleeds within the myometrium with each period, causing localised inflammation, swelling, and progressive damage to the uterine muscle. Over time, this leads to an enlarged, boggy uterus with a thickened, disrupted myometrium.

The junctional zone (JZ) -- the innermost layer of the myometrium that sits directly beneath the endometrium -- is the critical anatomical structure in adenomyosis. In healthy women, the junctional zone is thin and well-defined. In adenomyosis, the JZ becomes thickened, irregular, and invaded by endometrial tissue. This disruption of the junctional zone is now understood to be a key mechanism by which adenomyosis impairs fertility and implantation.

Historically, adenomyosis was thought to affect 20-35% of women, based on hysterectomy specimens. However, modern imaging studies using transvaginal ultrasound (TVS) and MRI have revealed a much higher prevalence -- particularly among women of reproductive age.

Prevalence Data

• General population: Recent imaging-based studies estimate that adenomyosis affects approximately 20-35% of women of reproductive age.
• Infertile women: Prevalence is significantly higher in women undergoing fertility evaluation. A 2023 systematic review published in Human Reproduction Update found adenomyosis in 20-38% of infertile women undergoing ultrasound assessment.
• IVF populations: Among women undergoing IVF, adenomyosis is detected in 20-25% of cases, with some studies reporting rates up to 34%.
• Recurrent implantation failure: In women with recurrent IVF implantation failure, the prevalence of adenomyosis jumps to 24-53%.
• Recurrent miscarriage: Adenomyosis is found in 15-28% of women with recurrent pregnancy loss.

Co-existence with Endometriosis

Adenomyosis and endometriosis frequently co-exist. Studies report that 20-80% of women with adenomyosis also have endometriosis, and vice versa. The two conditions share common pathogenic mechanisms -- including retrograde menstruation, tissue injury and repair (TIAR) theory, and oestrogen dependence -- which explains their frequent overlap. When both conditions are present, the cumulative impact on fertility may be greater than either condition alone.

The Indian Context

In India, population-level data on adenomyosis prevalence is limited. A 2025 review published in The Lancet Regional Health - Southeast Asia highlighted adenomyosis as a significantly under-researched condition in India and Sri Lanka, noting that most Indian studies come from tertiary care centres and may underestimate true prevalence. The review called for greater awareness among clinicians and dedicated research into the condition's epidemiology in the subcontinent.

Indian women face particular challenges with adenomyosis diagnosis: normalisation of heavy menstrual bleeding and painful periods, limited access to high-quality transvaginal ultrasound with sonographers trained in adenomyosis features, and a general lack of awareness of the condition among both patients and primary care providers.

Adenomyosis presents in two main forms, and the distinction is important for both fertility impact and treatment planning.

Diffuse Adenomyosis

This is the more common form. Endometrial tissue is spread throughout the myometrium in a widespread, non-localised pattern. The entire uterus (or large portions of it) is affected, leading to a globally enlarged, symmetrical uterus. Diffuse adenomyosis typically causes:

• Generalised uterine enlargement
• Widespread junctional zone thickening
• Heavy menstrual bleeding throughout the period
• Significant dysmenorrhea

Diffuse adenomyosis is more challenging to treat surgically because there is no discrete lesion to remove.

Focal Adenomyosis (Adenomyoma)

In focal adenomyosis, the endometrial tissue forms a circumscribed, tumour-like collection within the myometrium -- called an adenomyoma. This resembles a fibroid in appearance but is composed of endometrial glands and stroma rather than smooth muscle. Key features include:

• A localised mass within the uterine wall
• Can mimic a fibroid on imaging (but lacks the sharp borders and whorled pattern)
• May be amenable to surgical excision in selected cases
• Can affect fertility depending on size and location

Classification by Junctional Zone Involvement

Modern classification also considers the extent of junctional zone disruption:

• JZ thickening >12mm: Strong diagnostic criterion for adenomyosis on MRI
• JZ thickening 8-12mm: Suggestive, requires clinical correlation
• Asymmetric JZ thickening: Particularly associated with implantation failure

The exact cause of adenomyosis is not fully understood, but several theories have been proposed.

Leading Theories

• Tissue Injury and Repair (TIAR): The most widely accepted modern theory. Repeated injury to the junctional zone -- from menstruation, childbirth, uterine surgery, or chronic inflammation -- triggers a repair process that results in endometrial tissue invading the myometrium. This theory explains why adenomyosis is more common after uterine instrumentation.

• Invagination of the basal endometrium: The deepest layer of the endometrium may naturally invaginate (fold inward) into the myometrium through disruptions in the junctional zone. Hormonal and inflammatory factors may drive this process.

• Metaplasia: Cells within the myometrium may undergo metaplastic transformation into endometrial-like tissue under hormonal or inflammatory stimulation, particularly in the presence of oestrogen excess.

• Stem cell involvement: Endometrial stem/progenitor cells may aberrantly migrate into the myometrium and differentiate into endometrial glands and stroma. This theory is gaining support from molecular studies.

Risk Factors

• Prior uterine surgery: Caesarean section, myomectomy, dilatation and curettage (D&C), and endometrial ablation increase risk by disrupting the junctional zone
• Multiparity: Women who have had multiple pregnancies have higher rates, though adenomyosis is also found in nulliparous women
• Age: Risk increases with age, peaking in the 40s, though it is increasingly detected in younger women with improved imaging
• Endometriosis: Strong association -- having endometriosis significantly increases your risk of adenomyosis
• Early menarche: Starting menstruation before age 10 increases risk
• Short menstrual cycles: Cycles shorter than 24 days are associated with higher risk
• Heavy menstrual bleeding: Both a symptom and a risk factor, as heavy bleeding may contribute to junctional zone damage

Important Nuance for Fertility Patients

A critical point: adenomyosis is no longer considered exclusively a disease of older, multiparous women. Studies now consistently identify adenomyosis in young, nulliparous women -- including those who have never had uterine surgery. If you are under 35, have never been pregnant, and have symptoms suggestive of adenomyosis, do not let outdated assumptions prevent evaluation.

Adenomyosis symptoms overlap significantly with other gynaecological conditions, which contributes to diagnostic delay.

Common Symptoms

• Heavy menstrual bleeding (menorrhagia): The most common symptom. Periods are often prolonged (lasting more than 7 days), excessively heavy (requiring frequent pad changes or causing flooding), and may include large clots. In India, this chronic blood loss frequently leads to iron deficiency anaemia.

• Severe menstrual cramps (dysmenorrhea): Intense, cramping pain during periods that often worsens over time. The pain may be more diffuse across the lower abdomen compared to the focal cramps typical of fibroids. Pain may begin before the period starts and persist after bleeding stops.

• Chronic pelvic pain: Ongoing pelvic pain or discomfort between periods. This may be worse in the luteal phase (second half of the menstrual cycle) and can be associated with a sensation of heaviness or pressure in the pelvis.

• Painful intercourse (dyspareunia): Deep pain during sexual intercourse, particularly with deep penetration. This symptom overlaps with endometriosis and can significantly affect quality of life.

• Enlarged uterus: The uterus may become globally enlarged -- sometimes 2-3 times its normal size. This can cause abdominal bloating, a sense of fullness, or urinary frequency if the enlarged uterus presses on the bladder.

• Infertility: Difficulty conceiving or recurrent pregnancy loss may be the presenting complaint, particularly in younger women with adenomyosis that is otherwise asymptomatic or mildly symptomatic.

The Overlap Problem

Many of these symptoms overlap with uterine fibroids, endometriosis, and dysfunctional uterine bleeding. In clinical practice, adenomyosis is often misdiagnosed as fibroids or attributed to "normal" heavy periods. A 2024 study from India found that the average diagnostic delay for adenomyosis was 5-8 years from symptom onset, driven by the same cultural and healthcare system factors that delay endometriosis diagnosis.

Adenomyosis impairs fertility through multiple interconnected mechanisms. Understanding these helps explain why treatment strategies focus on suppressing the disease before embryo transfer.

1. Junctional Zone Disruption and Impaired Implantation

The junctional zone plays a critical role in embryo implantation. It generates coordinated contractions that help transport sperm and position the embryo for implantation. In adenomyosis, the junctional zone is thickened, irregular, and dysfunctional. This results in:

• Abnormal uterine contractions (dysperistalsis) that may physically expel embryos
• Disrupted endometrial-myometrial signalling during the implantation window
• A JZ thickness greater than 12mm on MRI has been consistently associated with reduced IVF implantation rates

A landmark study found that women with a JZ thickness exceeding 12mm had implantation rates approximately 50% lower than women with a normal JZ.

2. Altered Endometrial Receptivity

Adenomyosis fundamentally changes the endometrial environment. Research has demonstrated:

• Progesterone resistance in the endometrium overlying adenomyotic tissue
• Altered expression of key implantation markers (integrins, LIF, HOXA10)
• Abnormal decidualisation -- the process by which the endometrium prepares for embryo implantation
• Increased oxidative stress in the endometrial cavity

These molecular changes mean that even when a good-quality embryo reaches the uterus, the endometrium may not be able to support implantation.

3. Chronic Inflammation

Adenomyotic tissue generates a chronic inflammatory state within the myometrium and endometrium. Elevated levels of inflammatory cytokines (IL-6, IL-8, TNF-alpha), prostaglandins, and activated immune cells create a hostile environment for embryo implantation and early pregnancy development.

4. Impaired Uterine Contractility

Normal uterine peristalsis is essential for sperm transport, embryo positioning, and implantation. In adenomyosis, uterine contractions become dysregulated -- often hyperactive and uncoordinated. This dysperistalsis can physically displace embryos from the implantation site, contributing to both implantation failure and early pregnancy loss.

5. Increased Miscarriage Risk

Women with adenomyosis who do conceive face a significantly higher risk of miscarriage. A 2022 meta-analysis published in Human Reproduction found that adenomyosis was associated with a 2.2-fold increased risk of early pregnancy loss. The mechanisms include impaired placentation, chronic inflammation at the implantation site, and abnormal uterine contractility.

6. Obstetric Complications

Adenomyosis is also associated with adverse obstetric outcomes including:

• Preterm birth (1.7-2.1 fold increased risk)
• Placenta praevia
• Small for gestational age (SGA) babies
• Higher caesarean section rates
• Pre-eclampsia

Diagnosing adenomyosis has improved significantly with advances in non-invasive imaging. Historically, definitive diagnosis required histological examination of a hysterectomy specimen -- obviously not an option for women seeking fertility. Today, TVS and MRI can diagnose adenomyosis with high accuracy.

Transvaginal Ultrasound (TVS)

TVS is the first-line diagnostic tool for adenomyosis. In experienced hands, it has a sensitivity of 72-89% and specificity of 65-98% -- comparable to MRI. However, the accuracy is highly operator-dependent and requires specific training in adenomyosis features.

Key ultrasound features of adenomyosis:

• Asymmetric myometrial thickening: One wall of the uterus appears thicker than the other
• Myometrial cysts: Small, anechoic (dark) cysts within the myometrium, representing trapped endometrial glands
• Echogenic linear striations: Bright lines radiating from the endometrium into the myometrium (the "fan-shaped" or "Venetian blind" sign)
• Heterogeneous myometrium: Irregular texture of the uterine muscle with ill-defined areas of different echogenicity
• Subendometrial echogenic buds or islands: Bright spots just beneath the endometrial lining, representing endometrial tissue invading the JZ
• Globular, enlarged uterus: A symmetrically enlarged uterus without discrete fibroids
• Irregular or poorly defined junctional zone: The normally crisp border between endometrium and myometrium becomes blurred

MRI (Magnetic Resonance Imaging)

MRI is considered the gold standard for adenomyosis diagnosis when available. It provides the most precise measurement of junctional zone thickness and the best characterisation of disease extent.

Key MRI features:

• JZ thickness >12mm: The most reliable diagnostic criterion
• JZ thickening ratio: JZ max / myometrium thickness >40% is suggestive
• High signal foci on T2-weighted images: Representing islands of endometrial tissue within the myometrium
• Low-signal myometrial thickening on T2: Representing smooth muscle hypertrophy surrounding adenomyotic foci
• Diffuse vs focal pattern: MRI clearly distinguishes between diffuse adenomyosis and focal adenomyomas

MRI is particularly valuable for:

• Confirming an equivocal ultrasound diagnosis
• Surgical planning for focal adenomyomas
• Distinguishing adenomyosis from fibroids (a common clinical dilemma)
• Measuring JZ thickness to predict IVF outcomes

Histological Diagnosis

While hysterectomy specimens provide the traditional gold standard, endometrial biopsy or hysteroscopic-guided biopsy of the JZ can sometimes confirm adenomyosis in fertility patients. However, negative biopsies do not rule out the condition, as sampling may miss the affected areas.

Differentiating Adenomyosis from Fibroids

This is a common diagnostic challenge. Key distinguishing features:

Standard Diagnostic Tests in India

• Transvaginal Ultrasound (TVS) — First-line imaging — sensitivity 72-89% in experienced hands. Looks for myometrial cysts, asymmetric thickening, and heterogeneous myometrium.
• MRI Pelvis — Gold standard — precise JZ measurement, distinguishes adenomyosis from fibroids, and maps disease extent for treatment planning.
• Saline Sonohysterogram (SIS) — Assesses uterine cavity distortion from focal adenomyomas and helps rule out co-existing submucosal fibroids.
• AMH and Hormonal Panel — Assesses ovarian reserve — particularly important when adenomyosis coexists with endometriosis or when planning IVF.
• 3D Transvaginal Ultrasound — Enhanced visualization of the junctional zone and uterine anatomy. Increasingly used for JZ assessment when MRI is not available.

Treatment of adenomyosis in the fertility context is fundamentally different from treatment in women who have completed childbearing. The goal is not to eliminate the disease permanently, but to suppress it sufficiently to create a window of opportunity for embryo implantation and early pregnancy establishment.

GnRH Agonist Suppression Before IVF

This is the most widely studied and most commonly used approach for adenomyosis-related fertility treatment.

How it works: GnRH agonists (such as leuprolide/Lupron or triptorelin) suppress oestrogen production, creating a temporary menopausal state. This causes:

• Reduction in adenomyotic tissue volume
• Reduction in JZ thickness
• Decreased uterine inflammation
• Improved endometrial receptivity

Protocol: Typically 2-3 months (and sometimes up to 6 months) of GnRH agonist injections before embryo transfer. In many IVF protocols for adenomyosis, the approach is:

1. Ovarian stimulation and egg retrieval (fresh cycle)
2. Freeze all embryos
3. GnRH agonist suppression for 2-3 months
4. Frozen embryo transfer (FET) after suppression

Evidence: A 2024 systematic review in Reproductive BioMedicine Online found that GnRH agonist pre-treatment for 2-3 months significantly improved clinical pregnancy rates and live birth rates in women with adenomyosis undergoing FET. Women who received pre-treatment had approximately 1.5 times higher odds of clinical pregnancy compared to those who did not.

Limitations:

• Menopausal side effects (hot flushes, mood changes, joint pain, vaginal dryness)
• Bone density loss with prolonged use (>6 months)
• Adds 2-3 months to the treatment timeline
• Disease recurs after stopping treatment

Dienogest Pre-treatment

Dienogest (marketed as Visanne in India) is an oral progestogen with specific activity against endometriosis and adenomyosis.

Advantages:

• Oral medication (no injections)
• Fewer menopausal side effects than GnRH agonists
• Can shrink adenomyotic tissue and reduce JZ thickness

Evidence: Emerging studies suggest that 2-3 months of dienogest before FET may improve implantation rates, though the evidence base is smaller than for GnRH agonists. Some Indian fertility centres are now using dienogest as an alternative pre-treatment, particularly when patients cannot tolerate GnRH agonists.

Surgery for Focal Adenomyoma

When adenomyosis presents as a well-defined focal adenomyoma, surgical excision may be considered.

Adenomyomectomy:

• Laparoscopic or open excision of the focal adenomyoma
• Technically challenging because adenomyomas lack the clear capsule that fibroids have
• Higher risk of uterine wall weakening and incomplete excision compared to myomectomy for fibroids
• Requires 3-6 months recovery before conception

When surgery is considered:

• A discrete, focal adenomyoma causing significant cavity distortion
• Failed medical management with persistent symptoms
• Large focal adenomyoma (>3-4 cm) that may interfere with IVF
• Patient preference after informed discussion of risks and benefits

Important caveat: Surgery for diffuse adenomyosis is generally not recommended for fertility patients. There is no discrete lesion to remove, and extensive myometrial excision weakens the uterine wall and has high complication rates.

Uterine Artery Embolisation (UAE)

UAE has been used in some cases for adenomyosis, but it is generally not recommended for women planning pregnancy due to concerns about endometrial damage, ovarian reserve impact, and uterine wall integrity.

The Freeze-All Approach

The freeze-all strategy has become the standard of care for IVF in women with adenomyosis. Rather than performing a fresh embryo transfer in the stimulation cycle (when the uterine environment may be suboptimal), all embryos are frozen. This allows:

• Time for GnRH agonist or dienogest suppression
• A controlled FET cycle with optimised endometrial preparation
• Separation of the egg retrieval from the transfer, allowing focus on each step

Understanding how adenomyosis affects IVF outcomes helps set realistic expectations and guides treatment decisions.

Impact on IVF Success Rates

Multiple meta-analyses have examined the effect of adenomyosis on IVF outcomes:

• Clinical pregnancy rate: Reduced by approximately 28-30% compared to women without adenomyosis
• Live birth rate: Reduced by approximately 30-35%
• Miscarriage rate: Increased by approximately 2-fold (relative risk 1.7-2.2)
• Implantation rate: Reduced by approximately 23-28%

A comprehensive 2023 meta-analysis in Human Reproduction Update, which included over 15,000 IVF cycles, confirmed that adenomyosis significantly reduces clinical pregnancy rates (OR 0.72), live birth rates (OR 0.65), and increases miscarriage rates (OR 1.69).

Impact of Pre-treatment on Outcomes

The good news is that appropriate pre-treatment can substantially improve these outcomes:

• Women with adenomyosis who received GnRH agonist pre-treatment before FET had live birth rates of approximately 35-42%, compared to 22-28% without pre-treatment
• Clinical pregnancy rates improved from approximately 30-35% to 42-48% with GnRH agonist suppression
• The benefit was most pronounced in women with JZ thickness >12mm

Prognostic Factors

Several factors predict better or worse IVF outcomes in adenomyosis:

Better prognosis:

• Focal (vs diffuse) adenomyosis
• JZ thickness <12mm
• Younger age (<38)
• Normal uterine size
• Adequate pre-treatment suppression
• Good-quality embryos (particularly blastocysts)

Worse prognosis:

• Diffuse adenomyosis with severe JZ disruption
• JZ thickness >15mm
• Co-existing endometriosis with low ovarian reserve
• Prior multiple implantation failures
• Advanced maternal age

Cumulative Success Rates

While per-cycle success rates are lower with adenomyosis, cumulative success rates over multiple IVF cycles are encouraging. With appropriate pre-treatment and multiple FET attempts, cumulative live birth rates of 50-60% over 3-4 cycles are reported in the literature.

Understanding the financial implications is essential for treatment planning. Here is a realistic breakdown of adenomyosis-related fertility treatment costs in India.

Diagnostic Costs

• Transvaginal ultrasound (TVS): Rs 800-2,000
• MRI pelvis: Rs 6,000-15,000 (varies significantly by city and facility)
• Blood tests (AMH, hormonal panel): Rs 2,000-5,000

Medical Treatment Costs

• GnRH agonist injections (leuprolide/triptorelin): Rs 3,000-6,000 per monthly injection; 2-3 months = Rs 6,000-18,000
• Dienogest (Visanne): Rs 300-500 per month; 2-3 months = Rs 600-1,500

IVF Treatment Costs

• Complete IVF cycle with freeze-all: Rs 1.5-3.5 lakh (including stimulation, egg retrieval, embryo freezing)
• Frozen embryo transfer (FET) cycle: Rs 40,000-80,000 per transfer
• GnRH agonist pre-treatment + FET: Add Rs 10,000-20,000 to the FET cost
• Medications for FET preparation: Rs 5,000-15,000

Surgical Costs (if applicable)

• Laparoscopic adenomyomectomy: Rs 1-2.5 lakh
• Hysteroscopic assessment: Rs 20,000-40,000

Total Estimated Cost

For a typical adenomyosis fertility treatment pathway (IVF with freeze-all + GnRH suppression + FET):

• Single cycle: Rs 2-4.5 lakh
• Multiple cycles (2-3 FET attempts): Rs 3-7 lakh